Lionco Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
April 29, 2022 at 06:26 pm EDT
Share
Lionco Pharmaceutical Group Co.,Ltd. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported sales was CNY 734.89 million compared to CNY 1,000.35 million a year ago. Revenue was CNY 740.33 million compared to CNY 1,001 million a year ago. Net income was CNY 65.9 million compared to CNY 160.07 million a year ago. Basic earnings per share from continuing operations was CNY 0.09 compared to CNY 0.22 a year ago. Diluted earnings per share from continuing operations was CNY 0.09 compared to CNY 0.21 a year ago.
Lionco Pharmaceutical Group Co.,Ltd. is a China-based company principally engaged in the research and development, production and sales of chemical prescription medicine. The Company's products are mainly categorized in to three areas: parenteral nutrition agents, anti-infectious agents and digestive system agents. The lead product of its parenteral nutrition agents is Glutamine for injection; its anti-infectious agents include Cefodizime sodium for injection and Cefathiamidine for injection, among others; its digestive system agents include Omeprazole Sodium for injection and others. The Company operates its business in domestic market.
LIONCO PHARMACEUTICAL GROUP CO.,LTD. 
